ProKidney (NASDAQ:PROK - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.
Several other research firms have also issued reports on PROK. Weiss Ratings reissued a "sell (d-)" rating on shares of ProKidney in a report on Thursday, January 22nd. HC Wainwright initiated coverage on shares of ProKidney in a report on Tuesday, December 16th. They set a "buy" rating and a $12.00 price target on the stock. Finally, Jefferies Financial Group raised shares of ProKidney to a "strong-buy" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.40.
Check Out Our Latest Stock Analysis on PROK
ProKidney Stock Performance
NASDAQ PROK opened at $1.93 on Friday. The business's fifty day moving average is $2.15 and its 200 day moving average is $2.42. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $7.13. The company has a market capitalization of $580.60 million, a PE ratio of -3.71 and a beta of 1.75.
ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The company had revenue of $0.23 million during the quarter, compared to analysts' expectations of $0.00 million. On average, sell-side analysts forecast that ProKidney will post -0.57 EPS for the current year.
Institutional Trading of ProKidney
Several institutional investors and hedge funds have recently added to or reduced their stakes in PROK. Millennium Management LLC bought a new position in ProKidney in the 3rd quarter worth approximately $4,734,000. Artia Global Partners LP purchased a new stake in ProKidney during the 4th quarter valued at approximately $4,118,000. JPMorgan Chase & Co. raised its position in shares of ProKidney by 3,024.9% during the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company's stock valued at $988,000 after buying an additional 1,615,243 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of ProKidney by 63.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 1,503,886 shares of the company's stock worth $3,369,000 after buying an additional 583,983 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of ProKidney by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 1,197,530 shares of the company's stock worth $2,684,000 after buying an additional 100,748 shares in the last quarter. Institutional investors own 51.59% of the company's stock.
About ProKidney
(
Get Free Report)
ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.
ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
